V
Vasily Mamonov
Researcher at Russian Academy
Publications - 12
Citations - 536
Vasily Mamonov is an academic researcher from Russian Academy. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 6, co-authored 12 publications receiving 415 citations.
Papers
More filters
Journal ArticleDOI
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
K. John Pasi,Savita Rangarajan,Pencho Georgiev,Tim Mant,Michael Desmond Creagh,Toshko Lissitchkov,David H. Bevan,Steve Austin,Charles R. M. Hay,Inga Hegemann,Rashid S. Kazmi,Pratima Chowdary,Liana Gercheva-Kyuchukova,Vasily Mamonov,Margarita Timofeeva,Chang-Heok Soh,Pushkal Garg,Akshay Vaishnaw,Akin Akinc,Benny Sørensen,Margaret V. Ragni +20 more
TL;DR: Once‐monthly subcutaneous administration of fitusiran resulted in dose‐dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.
Journal ArticleDOI
Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
S. V. Antunes,S. Tangada,Oleksandra Stasyshyn,Vasily Mamonov,J. Phillips,Norma Guzman-Becerra,Areg Grigorian,Bruce M. Ewenstein,W.-Y. Wong +8 more
TL;DR: It is demonstrated that FEIBA prophylaxis significantly reduces all types of bleeding compared with on‐demand treatment, and the safety of prophyllaxis is comparable to that of on‐ demand treatment.
Journal ArticleDOI
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Jerzy Windyga,Toshko Lissitchkov,Oleksandra Stasyshyn,Vasily Mamonov,L. Rusen,J. L. Lamas,Myungshin Oh,Miranda Chapman,Sandor Fritsch,Borislava G. Pavlova,W.-Y. Wong,Brigitt E. Abbuehl +11 more
TL;DR: It is indicated that BAX326 is safe and efficacious in treating bleeds and routine prophylaxis in patients aged 12 years and older with haemophilia B.
Journal ArticleDOI
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran – results of the phase 1 inhibitor cohort
K. John Pasi,Toshko Lissitchkov,Vasily Mamonov,Tim Mant,Margarita Timofeeva,Catherine Bagot,Pratima Chowdary,Pencho Georgiev,Liana Gercheva-Kyuchukova,Kate Madigan,Huy Van Nguyen,Qifeng Yu,Baisong Mei,Craig Benson,Margaret V. Ragni +14 more
TL;DR: Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or without inhibitors as discussed by the authors.
Journal ArticleDOI
Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
TL;DR: FEIBA prophylaxis significantly reduced ABR and improved HRQoL in inhibitor patients, and the association between annualized bleeding rate (ABR) and physical HRZoL was tested.